Merrimack Pharmaceuticals Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
47,786.00
102,756.00
89,258.00
-
-
4,074
Cost of Goods Sold (COGS) incl. D&A
-
-
4,334.00
6,500.00
5,100.00
4,074
Gross Income
-
-
84,924.00
6,500.00
5,100.00
4,074
SG&A Expense
164,937.00
165,789.00
214,495.00
132,317.00
90,666.00
60,201
EBIT
119,740.00
66,256.00
129,571.00
-
95,766.00
64,275
Unusual Expense
800.00
-
-
23,076.00
5,202.00
1,300
Non Operating Income/Expense
627.00
813.00
917.00
8.00
10,318.00
6,430
Interest Expense
10,938.00
18,230.00
19,232.00
7,883.00
29,448.00
956
Pretax Income
130,685.00
83,559.00
147,787.00
169,508.00
118,403.00
68,462
Income Tax
-
-
-
13,224.00
42,399.00
7,695
Consolidated Net Income
130,685.00
83,559.00
147,787.00
156,284.00
76,004.00
60,767
Net Income
130,925.00
83,291.00
147,957.00
154,506.00
74,844.00
60,767
Net Income After Extraordinaries
130,925.00
83,291.00
147,957.00
157,272.00
621,716.00
81,028
Net Income Available to Common
130,925.00
83,291.00
147,957.00
151,740.00
129,642.00
68,506
EPS (Basic)
13.20
8.00
13.30
121.10
35.67
3.04
Basic Shares Outstanding
9,891.90
10,441.00
11,135.60
1,253.30
13,232.00
13,343
EPS (Diluted)
13.24
7.98
13.29
121.07
35.67
3.04
Diluted Shares Outstanding
9,891.90
10,441.00
11,135.60
1,253.30
13,232.00
13,343
EBITDA
117,151.00
63,033.00
125,283.00
132,317.00
90,666.00
60,201
Non-Operating Interest Income
166.00
114.00
99.00
276.00
895.00
1,299
Minority Interest Expense
240.00
268.00
170.00
1,778.00
1,160.00
-
Equity in Affiliates (Pretax)
-
-
-
-
800.00
3,200
About Merrimack Pharmaceuticals
View Profile
